Spectrum Pharmaceuticals, a biotechnology company focused on oncology, has appointed Steven M. Fruchtman, M.D., vice president of clinical development. Dr. Fruchtman will provide strategic planning and leadership for managing the company’s clinical development of belinostat, ZEVALIN and other pipeline products.

Dr. Fruchtman previously worked at Allos Therapeutics, where he helped develop pralatrexate for hematologic and oncologic indications. Dr. Fruchtman also was senior director of U.S. clinical development and medical affairs for Novartis Pharmaceuticals.